On 30 March 2026, China Biotech Services Holdings Limited approved the grant of 4.50 million ordinary shares under its August 2021 Share Award Scheme. The award represents approximately 0.46% of the company’s issued share capital. All shares were purchased by the scheme trustee on the open market at HK$0.81 apiece, translating to a total market value of HK$3.65 million.

The grant covers seven participants: • Executive Director and Chairman Liu Xiaolin—3.60 million shares (0.37% of shares in issue) • Directors of subsidiaries—0.50 million shares (0.05%) • Other employees—0.40 million shares (0.04%)

Awards vest immediately at nil consideration but are subject to a one-year lock-up during which disposals are prohibited. The scheme carries no performance targets or claw-back provisions.

Independent non-executive directors have approved the award to Mr Liu in accordance with GEM Listing Rule 23.04(1), and the transaction is classified as de minimis under Chapter 20, exempting it from shareholder approval and annual review.

Following this distribution, 91.24 million shares remain available for future grants under the Share Award Scheme. The company noted that the plan, adopted prior to the revised Chapter 23 of the GEM Listing Rules, will comply with transitional arrangements for existing share schemes.